76 ( 15 % ) patients taking placebo , 55 ( 11 % ) patients taking study drug every 2 weeks , and 71 ( 14 % ) patients taking study drug every 4 weeks reported serious adverse events ; relapse , pneumonia , and urinary tract infection were the most common .